The study, conducted on 399 patients, met its primary efficacy endpoint with a reduction of 75 percent of COVID-19 infection in the group treated with daily oral administration of Ivermectin compared to the placebo group. 

‘This is the 16th positive, statistically significant trial’…

https://www.uncoverdc.com/2023/02/10/gold-standard-rct-from-gates-funded-company-proves-ivermectin-works-against-covid/

EDIT ADDED

Meanwhile, even though MedinCell’s confirmation of Ivermectin as a safe and effective treatment against COVID-19 is incredible and the trial results are gold, its future plans for an injectable Ivermectin are questionable. As MedinCell CEO Douat remarked, the pharmaceutical technology company hopes to use its proprietary BEPO technology to produce a single injection of a long-acting formulation of Ivermectin. While the move will undoubtedly be hugely profitable for MedinCell, its proprietary BEPO® delivery system uses a combination of a diblock (DB) and a triblock (TB) polyethylene glycol-polyester copolymer. Off the bat, that part sets the sirens off.